-
-
-
-
-
-
-
Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
-
-
-
-
-
-
-
Real-world Leqembi study shows 82% of Alzheimer's patients stable
-
-
-
-
-
-
-
FDA extends review of Praxis drug for rare epilepsy to December 2026
-
-
-
-
-
-
-
FDA advisory panel votes 9-0 in favor of Moderna's mRNA flu vaccine
-
-
-
-
-
-
-
Praxis pauses vormatrigine study after trial misses primary endpoint
-
-
-
-
-
-
-
AstraZeneca's camizestrant wins EU panel backing for breast cancer
-
-
-
-
-
-
-
AbbVie presents inflammatory bowel disease data at medical conference
-
6,011 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving Hot FDA News reports.

